US2004058982A1PendingUtilityA1

Pharmaceutical compositions

58
Assignee: BIOAVAILABILITY SYSTEM LLCPriority: Feb 17, 1999Filed: Apr 25, 2003Published: Mar 25, 2004
Est. expiryFeb 17, 2019(expired)· nominal 20-yr term from priority
Inventors:James W. Harris
A23L 2/39A61K 31/4433A61K 31/337C07D 493/20A61K 31/497A23L 2/06A61K 31/495A61K 31/4418A23L 33/105A61K 31/665A61K 31/407C07D 493/10A61K 31/427A61K 38/00A61K 47/22A61K 31/4725A61K 31/341A61K 31/34A61K 31/499A61K 47/00
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions, methods, etc. for addressing the first-pass effect.

Claims

exact text as granted — not AI-modified
1 . A method of inhibiting the first-pass effect of a material taken orally by a patient which is subject to the first-pass effect, comprising the step of co-administering to said patient said material and a compound comprising one of the following cores:  
       
         
           
           
               
               
           
         
       
       wherein said material is selected from the group consisting of: 
 amprenavir  
 saquinavir  
 tipranavir  
 VX-950  
 VX-702  
 VX-175  
 VX-385  
 BILN 2061  
 ONO-4128  
 paclitaxel  
 TMC114  
 docetaxel  
 HCV-371, and  
 VP 50406.  
 
     
     
         2 . A composition comprising a material and a compound comprising one of the following cores:  
       
         
           
           
               
               
           
         
       
       wherein said material is selected from the group consisting of: 
 amprenavir  
 saquinavir  
 tipranavir  
 VX-950  
 VX-702  
 VX-175  
 VX-385  
 BILN 2061  
 ONO-4128  
 paclitaxel  
 TMC114  
 docetaxel  
 HCV-371, and  
 VP 50406.

Join the waitlist — get patent alerts

Track US2004058982A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.